1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Yeon Hee Park: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer Ribociclib with fulvestrant, Physician's choice treatments group - Breast Cancer Metastatic | Phase 2 | Not yet recruiting | Yeon Hee Park | 272 | 2026-02-01 | 2025-12-24 |
| Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer Sacituzumab Govitecan with pegfilgrastim - Breast Cancer Metastatic | Phase 2 | Recruiting | Yeon Hee Park | 40 | 2025-07-03 | 2025-08-28 |
Fulvestrant (1) · pegfilgrastim (1) · ribociclib (1) · sacituzumab govitecan (1)
South Korea (1)